Cargando…

Effect of Sacubitril/Valsartan on the Right Ventricular Function and Pulmonary Hypertension in Patients With Heart Failure With Reduced Ejection Fraction: A Systematic Review and Meta‐Analysis of Observational Studies

BACKGROUND: Sacubitril/valsartan (S/V) demonstrated significant effects in improving left ventricular performance and remodeling in patients with heart failure with reduced ejection fraction. However, its effects on the right ventricle remain unclear. This systematic review and meta‐analysis aimed t...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhang, Jing, Du, Le, Qin, Xiaohan, Guo, Xiaoxiao
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2022
Materias:	Systematic Review and Meta‐analysis
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9238626/ https://www.ncbi.nlm.nih.gov/pubmed/35470677 http://dx.doi.org/10.1161/JAHA.121.024449

Ejemplares similares

Real-World Safety of Sacubitril/Valsartan in Women and Men With Heart Failure and Reduced Ejection Fraction: A Meta-analysis
por: Nuechterlein, Kaitlin, et al.
Publicado: (2021)

Effects of Sacubitril/Valsartan on the Right Ventricular Arterial Coupling in Patients with Heart Failure with Reduced Ejection Fraction
por: Masarone, Daniele, et al.
Publicado: (2020)

Sacubitril/valsartan in the treatment of systemic right ventricular failure
por: Zandstra, Tjitske E, et al.
Publicado: (2021)

The Effect of Sacubitril-Valsartan on Ventricular Arrhythmia Burden in Patients With Heart Failure With Reduced Ejection Fraction
por: Medeiros, Paulo, et al.
Publicado: (2023)

Sacubitril/Valsartan in Asian Patients with Heart Failure with Reduced Ejection Fraction
por: Dewan, Pooja, et al.
Publicado: (2019)

Sacubitril/valsartan affects pulmonary arterial pressure in heart failure with preserved ejection fraction and pulmonary hypertension
por: Codina, Pau, et al.
Publicado: (2022)

Efficacy and safety of sacubitril/valsartan in heart failure compared to renin–angiotensin–aldosterone system inhibitors: a systematic review and meta-analysis of randomised controlled trials
por: Hernandez, Adrian V., et al.
Publicado: (2023)

Reduction of Pulmonary Hypertension After Transition to Sacubitril/Valsartan in Patients With Heart Failure With Preserved Ejection Fraction
por: Burgdorf, Christof, et al.
Publicado: (2021)

Sacubitril/Valsartan in the Treatment of Right Ventricular Dysfunction in Patients With Heart Failure With Reduced Ejection Fraction: A Real-world Study
por: Yang, Ying, et al.
Publicado: (2022)

Cost-effectiveness of sacubitril/valsartan in the treatment of heart failure with reduced ejection fraction
por: McMurray, John J V, et al.
Publicado: (2018)

Focused Treatment of Heart Failure with Reduced Ejection Fraction Using Sacubitril/Valsartan
por: Liu, Rex C.
Publicado: (2018)

ECG Monitoring of Reactions to Sacubitril-valsartan in Heart Failure with Reduced Ejection Fraction
por: Kang, Min-Kyung
Publicado: (2020)

Combination of ivabradine and sacubitril/valsartan in patients with heart failure and reduced ejection fraction
por: Lee, Ying‐Hsiang, et al.
Publicado: (2021)

The PARAGON-HF trial: the sacubitril/valsartan in heart failure with preserved ejection fraction
por: Gronda, Edoardo, et al.
Publicado: (2020)

Effects of Sacubitril/Valsartan on Serum Lipids in Heart Failure With Preserved Ejection Fraction
por: Selvaraj, Senthil, et al.
Publicado: (2021)

Safety and tolerability of Sacubitril/Valsartan in heart failure patient with reduced ejection fraction
por: Khan, Muhammad Nauman, et al.
Publicado: (2023)

Sacubitril–valsartan as a treatment for apparent resistant hypertension in patients with heart failure and preserved ejection fraction
por: Jackson, Alice M, et al.
Publicado: (2021)

Reverse remodelling by sacubitril/valsartan predicts the prognosis in heart failure with reduced ejection fraction
por: Moon, Mi‐Gil, et al.
Publicado: (2021)

Outcomes with sacubitril/valsartan in outpatients with heart failure and reduced ejection fraction: The ARIADNE registry
por: Maggioni, Aldo P., et al.
Publicado: (2022)

The comparative effects of sacubitril/valsartan versus enalapril on pulmonary hypertension due to heart failure with a reduced ejection fraction
por: Zhao, Ying, et al.
Publicado: (2022)

Left ventricular longitudinal systolic function analysed by 2D speckle-tracking echocardiography in heart failure with preserved ejection fraction: a meta-analysis
por: Morris, Daniel Armando, et al.
Publicado: (2017)

Sacubitril/Valsartan Improves Left Atrial and Ventricular Strain and Strain Rate in Patients with Heart Failure with Reduced Ejection Fraction
por: Brás, Pedro Garcia, et al.
Publicado: (2023)

Changing the treatment of heart failure with reduced ejection fraction: clinical use of sacubitril-valsartan combination
por: Kaplinsky, Edgardo
Publicado: (2016)

Early Effects of Sacubitril/Valsartan on Exercise Tolerance in Patients with Heart Failure with Reduced Ejection Fraction
por: Vitale, Giuseppe, et al.
Publicado: (2019)

Effects of sacubitril valsartan on clinical and echocardiographic parameters of outpatients with heart failure and reduced ejection fraction
por: Landolfo, Matteo, et al.
Publicado: (2020)

Sacubitril/Valsartan in Advanced Heart Failure With Reduced Ejection Fraction: Rationale and Design of the LIFE Trial
por: Mann, Douglas L., et al.
Publicado: (2020)

Sacubitril/valsartan in patients with heart failure with reduced ejection fraction with end‐stage of renal disease
por: Lee, Seonhwa, et al.
Publicado: (2020)

Rationale for and Practical Use of Sacubitril/Valsartan in the Patient’s Journey with Heart Failure and Reduced Ejection Fraction
por: Gori, Mauro, et al.
Publicado: (2021)

Clinical Effectiveness of Sacubitril/Valsartan Among Patients Hospitalized for Heart Failure With Reduced Ejection Fraction
por: Greene, Stephen J., et al.
Publicado: (2021)

Effects of Sacubitril-Valsartan in Heart Failure With Preserved Ejection Fraction in Patients Undergoing Peritoneal Dialysis
por: Fu, Sha, et al.
Publicado: (2021)

Sacubitril/valsartan versus angiotensin inhibitors and arrhythmia endpoints in heart failure with reduced ejection fraction
por: Fernandes, Amanda D.F., et al.
Publicado: (2021)

Effects of Sacubitril/Valsartan on biomarkers of fibrosis and inflammation in patients with heart failure with reduced ejection fraction
por: Bolla, Giovanni Battista, et al.
Publicado: (2022)

Efficacy and Dosage Pattern of Sacubitril/Valsartan in Chinese Heart Failure with Reduced Ejection Fraction Patients
por: Cheang, Iokfai, et al.
Publicado: (2022)

Effects of sacubitril-valsartan on central and obstructive apneas in heart failure patients with reduced ejection fraction
por: Wang, Youmeng, et al.
Publicado: (2022)

Cancer Mortality in Trials of Heart Failure With Reduced Ejection Fraction: A Systematic Review and Meta‐Analysis
por: Tini, Giacomo, et al.
Publicado: (2020)

Prescription of Sacubitril/Valsartan in Patients with Heart Failure and Reduced Ejection Fraction Attending an Outpatient Heart Failure Clinic
por: Rizzo, M, et al.
Publicado: (2020)

Acute pulmonary pressure change after transition to sacubitril/valsartan in patients with heart failure reduced ejection fraction
por: Tran, Jeffrey S., et al.
Publicado: (2021)

Pharmacodynamic and Pharmacokinetic Profiles of Sacubitril/Valsartan (LCZ696) in Patients with Heart Failure and Reduced Ejection Fraction
por: Kobalava, Zhanna, et al.
Publicado: (2016)

Sacubitril/Valsartan Improves Autonomic Function and Cardiopulmonary Parameters in Patients with Heart Failure with Reduced Ejection Fraction
por: Giallauria, Francesco, et al.
Publicado: (2020)

Early experience of Sacubitril–Valsartan in heart failure with reduced ejection fraction in real‐world clinical setting
por: Nordberg Backelin, Charlotte, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_8vht00k0d48io80b05luvv7tfe